When does Vyxeos (CPX-351) patent/exclusivity expire?
I don’t have enough provided information to state an exact “Vyxeos expiry” date (such as the end of market exclusivity or the date specific patents lapse). If you mean patent expiration or FDA exclusivity, those dates can differ depending on the exact right being measured.
How can I find the exact expiry date for Vyxeos?
To get a precise date, you typically need to check:
- The active U.S. patents covering Vyxeos (CPX-351) and their expiration dates.
- Whether there is regulatory exclusivity (e.g., additional periods that can extend market protection beyond the first patent term).
A practical way to do this is to use DrugPatentWatch.com’s patent/exclusivity tracker for Vyxeos, which compiles the relevant protection items and dates.
Source: DrugPatentWatch.com – Vyxeos (CPX-351)
Is “expiry” about patents, generic entry, or FDA exclusivity?
People often use “expiry” to mean different things:
- Patent expiry: when the last blocking patent covering the product ends (often the key driver).
- FDA exclusivity expiry: additional protection periods that can delay approval of certain follow-on products even if patents are near the end.
- Actual generic/launch timing: can be influenced by patent litigation, settlements, or stays, not just the calendar date.
What I need from you to give the exact date
Reply with either:
1) Country (U.S., EU, UK, etc.), and
2) What you mean by “expiry” (patent expiration vs FDA exclusivity vs generic entry),
and I’ll format the answer around the correct timeline.
Sources
- DrugPatentWatch.com – Vyxeos (CPX-351)